Drugs / AP-PA02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04596319 | Dec 2020 → Dec 2022 | Pseudomonas aeruginosa infectious disease, cystic fibrosis, respiratory tract infectious disorder | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05616221 | Jan 2023 → Jul 2024 | Pseudomonas aeruginosa infectious disease, bronchiectasis, respiratory tract infectious disorder | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP-PA02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05616221 ↗ |
| Modality | Other / unclassified | “AP-PA02 multi-bacteriophage therapeutic candidate administered by inhalation” NCT04596319 ↗ |
| Route | Inhaled | “Bacteriophage administered via inhalation” NCT04596319 ↗ |